Lantern Pharma Inc. — Form 10-Q Summary
Business Context and Reporting Period
Lantern Pharma is a clinical-stage biotechnology company developing targeted oncology therapies using its RADR® artificial intelligence, machine-learning and genomic-data platform. The portfolio included LP-100 and LP-300 in Phase II development, LP-184 and LP-284 in preclinical development, and an antibody-drug conjugate program. The filing covers the three and nine months ended September 30, 2022; financial statements are unaudited.
Financial Performance and Liquidity
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | None recognized | None recognized |
| Operating expenses | $2.15 million | $10.61 million |
| Research and development | $0.70 million | $6.35 million |
| General and administrative | $1.44 million | $4.26 million |
| Net loss | $2.26 million | $10.88 million |
| Loss per share | $0.21 | $1.00 |
| Cash used in operating activities | Not separately provided | $10.10 million |
There is no meaningful operating margin because the Company reported no operating revenue. At September 30, 2022, cash and cash equivalents were $39.26 million, marketable securities were $18.57 million, restricted cash was $0.54 million, and working capital was approximately $58.88 million. Total assets were $62.16 million and stockholders’ equity was $59.03 million. The Company reported no long-term debt; liabilities consisted primarily of accounts payable, accrued expenses and operating lease liabilities totaling $3.14 million.
Cash, cash equivalents and restricted cash declined by $12.73 million during the first nine months of 2022. Investing activities used $0.42 million, financing activities used $2.18 million, primarily for share repurchases, and foreign exchange reduced cash by $0.02 million. Management stated that existing cash and anticipated expenditures are expected to fund operating and capital requirements for at least 12 months from the filing date.
Material Changes Versus the Prior Comparable Period
- Third-quarter net loss decreased to $2.26 million from $4.05 million, primarily because research and development expense fell 76% to $0.70 million.
- Research and development expense increased 17% for the nine-month period, to $6.35 million from $5.41 million, reflecting higher research studies, consulting and development activity.
- General and administrative expense increased 22% in the quarter and 16% for the nine-month period, driven mainly by compensation, professional fees, travel and related public-company costs.
- Nine-month net loss increased to $10.88 million from $8.82 million. The prior-year period benefited from a $0.11 million PPP loan-forgiveness gain, while 2022 included higher marketable-securities and foreign-currency losses.
- A $0.935 million payment received from a service provider in July 2022 reduced reported LP-184 and related research expenses. The filing characterizes the payment as resolving differing views regarding the service-provider agreement.
- The Company repurchased 353,667 shares for approximately $2.48 million; the repurchase program terminated on July 31, 2022. Shares outstanding were 10,857,040 at September 30, 2022, versus 11,088,835 at December 31, 2021.
Guidance, Outlook, Risks and Unusual Items
Management expects research and development and general and administrative expenses, operating losses and funding needs to increase as clinical and preclinical programs advance. The Company expects to require substantial additional funding to complete clinical trials and may pursue equity financing, grants, commercial credit facilities or collaborations. Additional equity financing could dilute existing stockholders, while debt financing could impose fixed payment obligations and restrictive covenants.
- LP-300’s Phase II Harmonic trial was launched for never-smokers with advanced non-small cell lung cancer. LP-100 remained in a Phase II trial for metastatic castration-resistant prostate cancer.
- COVID-19-related staffing, supply-chain, manufacturing and clinical-site issues previously delayed development activities and could continue to adversely affect trial enrollment, manufacturing and liquidity.
- Marketable securities had $18.57 million of fair value and approximately $0.79 million of gross unrealized losses. The Company did not consider these losses to represent credit losses, but rising interest rates could adversely affect investment values.
- Future obligations include clinical-trial, manufacturing, research, licensing and milestone payments under agreements with service providers and licensors. Up to $0.50 million remained in escrow for potential Allarity Therapeutics enrollment-related payments, and additional milestones and royalties may apply.
- The Company has not obtained regulatory approval for any drug candidate, has not achieved profitability and may never generate product revenue or complete development successfully.
- Management concluded that disclosure controls and procedures were effective as of September 30, 2022, with no material changes to internal control over financial reporting during the quarter.
Most Important Facts for Investors to Verify
- Whether the stated cash runway remains adequate as LP-300, LP-100, LP-184 and LP-284 development spending increases.
- Clinical-trial enrollment, safety and efficacy updates, particularly for the LP-300 Harmonic trial and LP-100 Phase II program.
- The timing and terms of any additional financing, including potential dilution or debt restrictions.
- The status and financial impact of the $0.935 million service-provider payment, Allarity escrow milestones, licensing obligations and manufacturing commitments.
- The composition, maturity and market-value sensitivity of the Company’s marketable-securities portfolio.
- Whether the RADR® platform and pipeline programs produce licensing, collaboration or product revenue, since the filing reports no recognized operating revenue for the periods presented.